Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead†
Edoardo G. Giannini M.D., Ph.D.
Department of Internal Medicine, Gastroenterology Unit University of Genova, Genova, Italy
Search for more papers by this authorFabio Farinati M.D.
Department of Surgical and Gastroenterological Science, Gastroenterology Unit, University of Padova, Padova, Italy
Search for more papers by this authorFranco Trevisani M.D.
Department of Clinical Medicine, Unità di Semeiotica Medica Alma Mater Studiorum–University of Bologna, Bologna, Italy
Search for more papers by this authorEdoardo G. Giannini M.D., Ph.D.
Department of Internal Medicine, Gastroenterology Unit University of Genova, Genova, Italy
Search for more papers by this authorFabio Farinati M.D.
Department of Surgical and Gastroenterological Science, Gastroenterology Unit, University of Padova, Padova, Italy
Search for more papers by this authorFranco Trevisani M.D.
Department of Clinical Medicine, Unità di Semeiotica Medica Alma Mater Studiorum–University of Bologna, Bologna, Italy
Search for more papers by this authorPotential conflict of interest: Nothing to report.
References
- 1 Marrero JA, El-Serag HB. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 2010; doi:10.1002/hep.24033
- 2 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice %20Guidelines/HCCUpdate2010.pdf. Accessed January 19, 2011.
- 3 Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335.
- 4 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
- 5 Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297.
- 6 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
- 7 Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575.
- 8 Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532.
- 9 Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110.
- 10 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
